Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO

NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific abstracts featuring data from across its ophthalmic portfolio will be presented at two major eyecare meetings: * American Academy of Optometry’s (AAOpt) Annual meeting taking place September 30 – October 3, 2026, in Anaheim, California; and * American Academy of Ophthalmology’s (AAO) Annual Meeting, taking place October 9–12, 2026, in New Orleans, Louisiana. Harrow will have 13 presentations at AAOpt 2026 and two at AAO 2026, spanning dry eye disease, vernal keratoconjunctivitis (VKC), ocular inflammation, chronic blepharitis, and post-operative inflammation and pain. The research includes Phase 3 trial results, pooled Phase 3 analyses, 52-week long-term safety data, a randomized, double-masked comparative study, real-world evidence, and systematic reviews and meta-analyses. Featured Harrow products include VEVYE®, VERKAZIA®, FLAREX®, and BYQLOVI®.